355 related articles for article (PubMed ID: 30501907)
1. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.
Vrábel D; Pour L; Ševčíková S
Blood Rev; 2019 Mar; 34():56-66. PubMed ID: 30501907
[TBL] [Abstract][Full Text] [Related]
2. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
[TBL] [Abstract][Full Text] [Related]
3. NF-κB dysregulation in multiple myeloma.
Matthews GM; de Matos Simoes R; Dhimolea E; Sheffer M; Gandolfi S; Dashevsky O; Sorrell JD; Mitsiades CS
Semin Cancer Biol; 2016 Aug; 39():68-76. PubMed ID: 27544796
[TBL] [Abstract][Full Text] [Related]
4. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
5. Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro.
Qin Y; Sun CY; Lu FR; Shu XR; Yang D; Chen L; She XM; Gregg NM; Guo T; Hu Y
Leuk Res; 2012 Apr; 36(4):514-20. PubMed ID: 22226224
[TBL] [Abstract][Full Text] [Related]
6. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):16-34. PubMed ID: 23534949
[TBL] [Abstract][Full Text] [Related]
7. NF-kappaB in the pathogenesis and treatment of multiple myeloma.
Li ZW; Chen H; Campbell RA; Bonavida B; Berenson JR
Curr Opin Hematol; 2008 Jul; 15(4):391-9. PubMed ID: 18536579
[TBL] [Abstract][Full Text] [Related]
8. Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-κB pathway.
Tozawa K; Sagawa M; Kizaki M
Int J Oncol; 2011 Nov; 39(5):1117-22. PubMed ID: 21850367
[TBL] [Abstract][Full Text] [Related]
9. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
10. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.
Conticello C; Giuffrida R; Adamo L; Anastasi G; Martinetti D; Salomone E; Colarossi C; Amato G; Gorgone A; Romano A; Iannolo G; De Maria R; Giustolisi R; Gulisano M; Di Raimondo F
Leuk Res; 2011 Jan; 35(1):52-60. PubMed ID: 20674018
[TBL] [Abstract][Full Text] [Related]
11. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
Tiedemann RE; Schmidt J; Keats JJ; Shi CX; Zhu YX; Palmer SE; Mao X; Schimmer AD; Stewart AK
Blood; 2009 Apr; 113(17):4027-37. PubMed ID: 19096011
[TBL] [Abstract][Full Text] [Related]
12. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
[TBL] [Abstract][Full Text] [Related]
13. Signaling Pathways and Emerging Therapies in Multiple Myeloma.
Ramakrishnan V; D'Souza A
Curr Hematol Malig Rep; 2016 Apr; 11(2):156-64. PubMed ID: 26922744
[TBL] [Abstract][Full Text] [Related]
14. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
Zhao Y; Zhang K; Li G; Zhang X; Shi D
PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
[TBL] [Abstract][Full Text] [Related]
15. Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor κB pathway.
Takeda T; Tsubaki M; Kino T; Kawamura A; Isoyama S; Itoh T; Imano M; Tanabe G; Muraoka O; Matsuda H; Satou T; Nishida S
Int J Oncol; 2016 Jun; 48(6):2704-12. PubMed ID: 27035859
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
[TBL] [Abstract][Full Text] [Related]
17. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity.
Nakaya A; Sagawa M; Muto A; Uchida H; Ikeda Y; Kizaki M
Leuk Res; 2011 Feb; 35(2):243-9. PubMed ID: 20542334
[TBL] [Abstract][Full Text] [Related]
18. [Molecular pathogenesis of myeloma for the therapeutic targets].
Hanamura I
Nihon Rinsho; 2007 Dec; 65(12):2202-8. PubMed ID: 18069261
[TBL] [Abstract][Full Text] [Related]
19. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
[TBL] [Abstract][Full Text] [Related]
20. Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
Yan W; Li R; He J; Du J; Hou J
Cell Signal; 2015 Apr; 27(4):851-9. PubMed ID: 25643631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
